-
Dr. Feng Shen: Climb to the peak! The ASAP model continues to break through the depth and breadth of screening for Chinese liver cancer risk groups
China is a major country with liver cancer, and the incidence rate and mortality rate of liver cancer account for about half of the world’s total. Early identification of high-risk populations and early diagnosis of liver cancer are key to improving the overall survival rate of patients. Since the discovery of vitamin K in 1929,…
-
Comparison of ASAP Score and GALAD Score in Detecting Hepatocellular Carcinoma in Chronic Liver Disease Patients with Different Etiologies
Primary liver cancer ranks as the fourth most common malignancy and the second leading cause of cancer-related deaths in China, posing a severe threat to people’s lives and health. Early detection, diagnosis, and treatment are crucial for improving treatment outcomes. In 2019, Dr. Feng Shen and Dr. Tian Yang research team from Eastern Hepatobiliary Surgery…
-
ESMO China’s Voice | Dr. Yuhong Zhou: Surufatinib Combined with Gemcitabine in Second-Line Treatment Shows Promise for Improving Prognosis in Soft Tissue Sarcoma
The 2024 European Society for Medical Oncology (ESMO) Annual Meeting recently concluded in Barcelona, Spain, bringing together the world’s leading oncology experts. At this year’s conference, Dr. Yuhong Zhou from Zhongshan Hospital, Fudan University, presented a phase II multicenter clinical trial that explored the efficacy and safety of surufatinib combined with gemcitabine in soft tissue…
-
ESMO On-site Highlights | Dr. Shukui Qin’s LBA Study Breakthrough: DUBHE-H-308 Offers New Options for First-Line Liver Cancer Treatment
From September 13 to 17, 2024, the European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. At this prestigious conference, the DUBHE-H-308 study led by Dr. Shukui Qin from Nanjing Tianyinshan Hospital, affiliated with China Pharmaceutical University, was selected for an LBA oral presentation (Abstract No.: LBA38). On September 13, from…
-
ESMO China’s Voice | Academician Jia Fan, Dr. Jian Zhou, and Dr. Xinrong Yang’s Team: Using Personalized ctDNA Methylation Haplotypes to Monitor Minimal Residual Disease After Curative Resection for Liver Cancer
The ESMO Annual Meeting 2024, held from September 13 to 17 in Barcelona, Spain, showcased the latest breakthroughs in oncology. Among them was a new study from the team led by Academician Jia Fan, Dr. Jian Zhou, and Dr. Xinrong Yang from Zhongshan Hospital, Fudan University, in collaboration with Burning Rock Biotech. The research, which…
-
99.9% HIV-Free! Lenacapavir Shows Outstanding Results in Long-Acting PrEP Trial
Key Data from the PURPOSE 2 Trial PURPOSE 2 is a Phase III, double-blind, multicenter, randomized study comparing the safety and efficacy of Lenacapavir administered as a subcutaneous injection every…
-
Exclusive Interview with Dr. Huilai Zhang: A Detailed Look at the 5th Tianjin International Lymphoma Conference
From September 6 to 8, 2024, the 5th Tianjin International Lymphoma Conference was successfully held. The conference featured 12 specialized sessions, including immunotherapy, translational research, and new drug development, creating a platform that fosters international academic exchange and cooperation. During the event, Hematology Frontier had the privilege of interviewing the conference chair, Dr. Huilai Zhang…
-
Dr. Robert Negrin: An In-Depth Analysis of Immunomodulatory Mechanisms and Transplantation
In the field of hematopoietic stem cell transplantation (HSCT), immunomodulatory mechanisms play a crucial role, affecting not only the success rate of the transplant but also the recipient’s tolerance to the graft and their long-term health post-transplant. At the 12th Lu Daopei Hematology Academic Forum, Dr. Robert Negrin, former Chief of the Blood and Marrow…
Connecting Medical Expertise through Media